期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

聚乙二醇重组人干扰素及其药品通用名称命名

PEGylated Recombinant Human Interferon and Nomenclature
原文传递
导出
摘要 越来越多的聚乙二醇修饰蛋白研发上市。为适应这类制品的发展,与之相关的中国药品通用名命名原则也需要不断更新。介绍了PEG修饰蛋白技术的发展以及WHO国际非专利药品名(INN)命名委员会对这类制品的命名情况,讨论了我国对这类制品的命名原则和方法。 A lot of PEGylated proteins have been approved. Therefore, the naming scheme of Chinese Approved Drug Name relating to this kind of products must be revised to adapting their development. The progress of PEGylation technology and INN for these drugs were introduced. The nomenclature for PEGylated recombinant protein in China was discussed.
作者 任跃明
机构地区 国家药典委员会
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2014年第6期105-109,共5页 China Biotechnology
关键词 聚乙二醇 重组人干扰素 药品通用名称 PEGylation Recombinant human interferon Nomenclature
分类号 Q819 [生物学—生物工程]
  • 相关文献

参考文献23

  • 1Kang J S, Deluca P P, Lee K C. Emerging PEGylated drugs. Expert Opin Emerg Drugs ,2009,14 ( 2 ) :363-380.
  • 2Bailon P I, Won C Y. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv, 2009,6 ( 1 ) : 1-16.
  • 3Franccsco M Vcronese, Anna Mero. The impact of PEGylafion on biological therapies. Biodrugs, 2008, 22 (5) : 315-329.
  • 4Robert W Payne, Brian M Murphy, Mark Coruell. Product development issues for PEGylated proteins. Pharmaceutical Development and Technology, 2011, 16 ( 5 ) : 423-440.
  • 5Fee C J, Van Alstine J A. PEG-proteins: Reaction engineering and separation issues. Chem Engineer Sci, 2006,61:924-939.
  • 6Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylafion. Drug Deliv, 2006,13:399-409.
  • 7Fee C J. Size comparison between proteins PEGylated with branched and linear Poly( ethylene glycol) molecules. Biotechnol Biotechnol Bioengineer, 2007,98:725-731.
  • 8WHO. 56th Consultation on International Nonproprietary Names for Pharmaceutical Substances Executive Summary. 09/2013. http ://www. who. int/medicines/services/inn/56th _ Executive _ Summary. pdf? ua = 1.
  • 9任跃明.国际非专利药品名(INN)在我国生物制品命名领域的应用[J].中国药品标准,2008,9(3):189-194. 被引量：4
  • 10《中国药典》.2010年版.三部.附录5.

二级参考文献9

  • 1[1]Guidelines on the Use of INNs for Pharmaceutical Substances (1997) (WHO/PHARMS/NOMI570).
  • 2[2]The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 (WHO/PSM/QSM/2006.3).
  • 3[3]International Nonpreprietary Names (INN) for Biological and Biotechnological Substances (INN Working Document 05.179/ update November 2007).
  • 4[4]Definition of INNs for substances prepared by biotechnolngy,WHO/ Pharm S/Nom 1348(1992).
  • 5[5]44th Consuhation on International Nonproprietary Names for Pharmaceutical Substances EXECUTIVE SUMMARY(Geneva,22-24 May 2007) (INN Working Document 07.214).
  • 6[6]Consultation on International Nonproprietary Names (INN) and biological products,INN Working Document 00.118 (20(12).
  • 7[7]INNs for biotechnolngical products:collaboration with other parties,WHO/Phann S/Nom 1763 (1999).
  • 8[8]INNs for recombinant vaccines and viruses,WHO/Pharm S/Nom 1719 (1998).
  • 9[9]INNs for biosynthetic vaccine,WHO/Phann S/Nom 1419 (1994).

共引文献3

中国生物工程杂志
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部